NYSE - Nasdaq Real Time Price USD

Elanco Animal Health Incorporated (ELAN)

17.09 +0.20 (+1.18%)
As of 12:51 PM EDT. Market Open.
Loading Chart for ELAN
DELL
  • Previous Close 16.89
  • Open 16.82
  • Bid 17.02 x 1800
  • Ask 17.04 x 1100
  • Day's Range 16.56 - 17.09
  • 52 Week Range 7.88 - 17.23
  • Volume 2,767,500
  • Avg. Volume 4,353,496
  • Market Cap (intraday) 8.446B
  • Beta (5Y Monthly) 1.30
  • PE Ratio (TTM) --
  • EPS (TTM) -2.50
  • Earnings Date Aug 5, 2024 - Aug 9, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 18.11

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

www.elanco.com

9,300

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ELAN

Performance Overview: ELAN

Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ELAN
14.70%
S&P 500
9.13%

1-Year Return

ELAN
82.59%
S&P 500
25.79%

3-Year Return

ELAN
48.02%
S&P 500
22.98%

5-Year Return

ELAN
45.56%
S&P 500
80.78%

Compare To: ELAN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ELAN

Valuation Measures

Annual
As of 5/8/2024
  • Market Cap

    8.35B

  • Enterprise Value

    13.77B

  • Trailing P/E

    --

  • Forward P/E

    17.79

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.88

  • Price/Book (mrq)

    1.34

  • Enterprise Value/Revenue

    3.12

  • Enterprise Value/EBITDA

    -61.47

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -27.87%

  • Return on Assets (ttm)

    1.39%

  • Return on Equity (ttm)

    -18.22%

  • Revenue (ttm)

    4.42B

  • Net Income Avi to Common (ttm)

    -1.23B

  • Diluted EPS (ttm)

    -2.50

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    352M

  • Total Debt/Equity (mrq)

    95.07%

  • Levered Free Cash Flow (ttm)

    388M

Research Analysis: ELAN

Company Insights: ELAN

Research Reports: ELAN

People Also Watch